Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Higher-income households with at least one user of GLP-1 class of weight loss drugs cut their grocery spending by nearly 9%, ...

A study in pigs has shown that the active ingredient in Ozempic and Wegovy directly boosts heart health, in addition to the ...

According to the study, participants taking Zepbound lost an average of 20.2% of their starting weight after 72 weeks, ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

Ozempic is a drug for diabetes, but it's also being used off-label for weight loss. Its active ingredient has inspired a new ...

(AP Photo/Manuel Balce Ceneta) WASHINGTON — Millions of Americans with obesity would be eligible to have popular weight-loss ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

a new class of weight loss medications offers unprecedented hope. Drugs like semaglutide (Wegovy, Ozempic) and tirzepatide ...

As the drugs have gained name recognition among adults, they’ve also become increasingly popular with children and adolescents. But are the safe?